Roch Doliveux, CEO of UCB
On “The Societal Value of an Enterprise”
Geneva, Thursday, May 2nd 2013, as of 6:00 PM
Dear Alumni,
It is with great pleasure that we invite you to this unique evening conference featuring Dr. Roch Doliveux (INSEAD MBA’81) on the “Societal Value of an Enterprise”.
Dr. Doliveux, as Chief Executive Officer and Chairman of the Executive Committee of UCB – a leading global biopharmaceutical company headquartered in Belgium – will share his views and lead the discussion on how companies can contribute and deal with society at a higher level.
Under Dr. Roch Doliveux’s 8 years of leadership, UCB has been transformed from a diversified group to a leading focused patient-centric biopharmaceutical company. Join us to learn about UCB’s case study and understand how Dr. Doliveux applied societal values as an essential part of this transformation:
Swissôtel Metropole, 34, Quai Général Guisan, Geneva
6:00 pm – 6:30 pm: Registration and Welcome Drink
6:30 pm – 7:30 pm: Conference Dr. Roch Doliveux
7:30 pm – 9:00 pm: Networking & Dinner Cocktail
Price: 75 CHF (Alumni Members) / 90 CHF (Non Members, Guests)
Please register & purchase your tickets online before Friday April 26th 2013 by clicking on the link below:
http://de.amiando.com/UCBDoliveux
Please note that after this date no cancellation will be possible, that the number of places is limited and that we will handle registrations on a first come first served basis. For any inquiries, please send an email to [email protected].
We look forward to seeing you there,
Leila Ojjeh
President INSEAD Alumni Association Geneva
Jonas Larsson
INSEAD Alumni Association Geneva, committee member
Roch Doliveux is UCB’s Chief Executive Officer and Chairman of the Executive Committee since eight years
. He joined UCB in October 2003 as Head of UCB’s Pharmaceutical business and Deputy Chairman of the Executive Committee. Under his leadership, UCB was transformed from a diversified group to a focused patient-centric biopharmaceutical leader recognized for its attractive growth prospects and rich pipeline.
He is a member of the Board of Directors of UCB, a member of the Board of Stryker Corporation in the US, a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), Chairman and member of the Board of the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, as well as a member of the Vlerick Business school. He also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which supports entrepreneurship in health and wellness. Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Roch Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in October 2011 and was bestowed the title of Commander of the Order of the Crown of Belgium in November 2012. He first joined the pharmaceutical industry with Ciba-Geigy (now Novartis) in Switzerland, Peru and France, and then with Schering-Plough Corporation in various positions in Belgium, France and the US, including President of Schering-Plough International. Before joining UCB, Roch Doliveux was Chief Executive Officer of Pierre Fabre Pharmaceuticals
